Qdolo is owned by Athena.
Qdolo contains Tramadol Hydrochloride.
Qdolo has a total of 1 drug patent out of which 0 drug patents have expired.
Qdolo was authorised for market use on 01 September, 2020.
Qdolo is available in solution;oral dosage forms.
Qdolo can be used as management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
The generics of Qdolo are possible to be released after 01 September, 2040.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11103452 | ATHENA | Tramadol hydrochloride solution |
Sep, 2040
(17 years from now) |
Drugs and Companies using TRAMADOL HYDROCHLORIDE ingredient
Market Authorisation Date: 01 September, 2020
Treatment: Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Dosage: SOLUTION;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic